
Biocon's Pebrilzo Receives EU Approval for HER2-Positive Breast Cancer
What Happened?
Biocon Limited has received marketing authorization from the European Commission for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer. This approval follows a positive opinion from the EMA's CHMP.
Key points
- Pebrilzo is the first biosimilar to receive EC marketing authorization under the EMA's new clinical approach.
- The approval follows a positive opinion from the EMA's CHMP on September 17, 2026.
- Pebrilzo is indicated for use with trastuzumab and chemotherapy for various stages of HER2-positive breast cancer.
- Biocon's CEO stated this approval marks a significant regulatory milestone for the company.
- This is Biocon's fifth oncology biosimilar approved in both Europe and the United States.
Key insights
- The approval may lead to increased competition in the biosimilar market for breast cancer treatments.
- Patients could benefit from more affordable treatment options due to the introduction of Pebrilzo.
- This development reinforces Biocon's position in the global oncology market.
Why it matters
This approval could enhance access to affordable treatments for patients with HER2-positive breast cancer.
Tags
Entities
Source
Business Standard

